- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
Cancer Research U.K. and its commercial arm, Cancer Research Technology (CRT), have joined with Astellas Pharma to conduct a two-year research program in the U.K. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.
Updated list of approved active moieties to which FDA has issued a Written Request for pediatric studies
For many years, Research Across America (RAA) has owned a mobile van affectionately known as “Barney” because of its color, purple!
Status: Completed, Condition Summary: Fibromyalgia
Status: Completed, Condition Summary: Sleep Disorders
YourEncore, which helps life sciences, consumer products and food companies solve complex innovation, compliance and productivity challenges, has launched the Regulatory Center of Excellence, to provide life sciences companies with industry-accomplished experts to guide them through complex regulatory requirements, from phase I trials through approval.
The Association of Clinical Research Professionals (ACRP) and the U.K.-based International Academy of Clinical Research (IAoCR), provider of accreditation, training and consultancy for clinical researchers, are collaborating to offer services and establish recognized global standards of clinical research.
Igenica Biotherapeutics, focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), has been awarded a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology.
The FDA has approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
BioSpecifics Technologies, a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the E.U., has injected the first patient in its placebo-controlled phase II clinical trial of CCH for the treatment of lipoma. The company expects to complete patient enrollment in this trial during the first quarter of 2015.
Theravance has appointed Michael W. Aguiar as president and CEO effective August 15, and as a member of the board of directors effective immediately. Aguiar plans to continue to as Theravance's senior vice president and chief financial officer until his replacement is identified and appointed.